Identification of protein-protein interaction inhibitors targeting vaccinia virus processivity factor for development of antiviral agents

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5054-5062

  Schormann, Norbert ^a   Sommers, Charnell Inglis ^a   Prichard, Mark N ^b   Keith, Kathy A ^b   Noah, James W ^c   Nuth, Manunya ^d   Ricciardi, Robert P ^d,e   Chattopadhyay, Debasish ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; DNA POLYMERASE; PROTEIN PROTEIN INTERACTION INHIBITOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; URACIL DNA GLYCOSIDASE; URACIL DNA GLYCOSIDASE D4; VACCINIA VIRUS PROCESSIVITY FACTOR; VIRULENCE FACTOR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VACCINIA VIRUS;

ANTIVIRAL AGENTS; CELL LINE; DNA GLYCOSYLASES; HUMANS; PROTEIN BINDING; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 80054715000     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00278-11     Document Type: Article

References (32)

1. Arkin, M. R., and J. A. Wells. 2004. Small-molecule inhibitors of proteinprotein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3:301-317. (Pubitemid 38499758)
2. Behbehani, A. 1983. The smallpox story: life and death of an old disease. Microbiol. Rev. 47:455-509. (Pubitemid 14210909)
3. Blazer, L. A., and R. R. Neubig. 2009. Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. Neuropsychopharmacol. Rev. 34:126-141.
4. Boyle, K. A., L. Arps, and P. Traktman. 2007. Biochemical and genetic analysis of the vaccinia virus d5 protein: multimerization-dependent ATPase activity is required to support viral DNA replication. J. Virol. 81:844-859. (Pubitemid 46067910)
5. Briz, V., E. Poveda, and V. Soriano. 2006. HIV entry inhibitors: mechanisms of action and resistance pathways. Antimicrob. Chemother. 57:619-627.
6. D'Costa, S. M., et al. 2010. Vaccinia H5 is a multifunctional protein involved in viral DNA replication, postreplicative gene transcription, and virion morphogenesis. Virology 401:49-60.
7. DeClercq, E. 2004. Antiviral drugs in current clinical use. J. Clin. Virol. 30:115-133. (Pubitemid 38582018)
8. De Silva, F. S., and B. Moss. 2005. Origin-independent plasmid replication occurs in vaccinia virus cytoplasmic factories and requires all five known poxvirus replication factors. Virol. J. 2:23.
9. De Silva, F. S., and B. Moss. 2003. Vaccinia virus uracil DNA glycosylase has an essential role in DNA synthesis that is independent of its glycosylase activity: catalytic site mutations reduce virulence but not virus replication in cultured cells. J. Virol. 77:159-166. (Pubitemid 36004956)
10. Dömling, A. 2008. Small molecular weight protein-protein interaction antagonists - an insurmountable challenge? Curr. Opin. Chem. Biol. 12:281-291.
11. Dropulic, L. K., and J. I. Cohen. 2010. Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Clin. Pharmacol. Ther. 88:610-619.
12. Druck Shudofsky, A. M., J. E. Y. Silverman, D. Chattopadhyay, and R. P. Ricciardi. 2010. Identification of vaccinia D4 point mutants that are defective in processivity yet retain UDG catalytic activity and are functional in A20 and DNA binding. J. Virol. 84:12325-12335.
13. Esté, J. A., and A. Telenti. 2007. HIV entry inhibitors. Lancet 370:81-88. (Pubitemid 47018315)
14. Evans, E., N. Klemperer, R. Ghosh, and P. Traktman. 1995. The vaccinia virus D5 protein, which is required for DNA replication, is a nucleic acid-independent nucleoside triphosphatase. J. Virol. 69:353-361.
15. Harden, E. A., R. Falshaw, S. M. Carnachan, E. R. Kern, M. N. Prichard. 2009. Virucidal activity of polysaccharide extracts from four algal species against herpes simplex virus. Antiviral Res. 83:282-289.
16. Hays, J. N. 2005. Epidemics and pandemics: their impacts on human history. ABC-CLICO, Inc., Santa Barbara, CA.
17. Hidaka, H., et al. 1978. A novel vascular relaxing agent. N-(6-Aminohexyl)-5-chloro-1napthalensulfonamide which affects vascular smooth muscle actomyosin. J. Pharmacol. Exp. Ther. 207:8-15. (Pubitemid 9079150)
18. Hou, Y., et al. 2008. Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assay. J. Biomol. Screen. 13:406-414. (Pubitemid 351793981)
19. Ishii, K., and B. Moss. 2002. Mapping interaction sites of the A20R protein component of the vaccinia virus DNA replication complex. Virology 303:232-239. (Pubitemid 36069188)
20. Iversen, P. W., B. J. Eastwood, G. S. Sittampalam, and K. L. Cox. 2006. A comparison of assay performance measures in screening assays: signal windows, Z′ factor, and assay variability ratio. J. Biomol. Screen. 11:247-252.
21. Jordan, R., et al. 2009. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 53:1817-1822.
22. Koplow, D. A. 2003. Smallpox: the fight to eradicate a global scourge. University of California Press, Berkeley, CA.
23. Kruger, W., et al. 2005. A yellow fluorescent protein-based assay for high-throughput screening of glycine and GABAA receptor chloride channels. Neurosci. Lett. 380:340-345. (Pubitemid 40616108)
24. Llano-Sotelo, B., R. P. Hickerson, L. Lancaster, H. F. Noller, and A. S. Mankin. 2009. Fluorescently labeled ribosomes as a tool for analyzing antibiotic binding. RNA 15:1597-1604.
25. Nuth, M., et al. 2011. Identification of inhibitors that block vaccinia virus infection by targeting the DNA synthesis processivity factor D4. J. Med. Chem. 54:3260-3267.
26. Prichard, M. N., et al. 2007. Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob. Agents Chemother. 51:1795-1803. (Pubitemid 46744160)
27. Rouleau, N., S. Turcotte, M. H. Mondou, P. Roby, and R. Bossé. 2003. Development of a versatile platform for nuclear receptor screening using AlphaScreen. J. Biomol. Screen. 8:191-197.
28. Royer, C. A., and S. F. Scarlata. 2008. Fluorescence approaches to quantifying biomolecular interactions. Methods Enzymol. 450:79-106.
29. Schormann, N., et al. 2007. Crystal structure of vaccinia virus uracil-DNA glycosylase reveals dimeric assembly. BMC Struct. Biol. 7:45.
30. Stanitsa, E. S., L. Arps, and P. Traktman. 2006. Vaccinia virus uracil DNA glycosylase interacts with the A20 protein to form a heterodimeric processivity factor for the viral DNA polymerase. J. Biol. Chem. 281:3439-3451. (Pubitemid 43845959)
31. Traktman, P. 1996. Poxvirus DNA replication, p. 775-798. In M. L. Depamphilis (ed.), DNA replication in eukaryotic cells. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
32. Zhang, J.-H, T. D. Y. Chung, and K. P. Oldenburg. 1999. A simple statistical parameter for use in evaluation of high throughput screening assays. J. Biomol. Screen. 4:67-73. (Pubitemid 29278954)